A compound of Formula (I), (II), (III), (IV) or (V), or a pharmaceutically acceptable salt thereof:
- wherein the compound of Formula (I) is:
- wherein:
- X3 is:
- (1) —CH(CH3)2;
- (2) —C(CH3)3;
- Y3 is —C(O)—C6H5 or D1;
- Z3 is:
- R10 is:
- (1) —C(O)—(CH2)k—CH3;
- (2) —O—CH2—CH═CH2;
- (3) a hydrogen;
- (4) methyl;
- (5) methoxy;
- (6) cyclopentyl;
- (7) halo;
- (8) —O—CH2—C(O)—ND1-CH3;
- (9) cyano;
- (10) —CH2—CH═CH2;
- or
- R11 is a hydrogen, methyl or a halo;
- or
- R10 and R11 taken together are W4—U4—V4;
- wherein W4—U4—V4 is
- (1) —CH═C(R14)—ND1-;
- (2) —CH═CH—CH2—;
- (3) —CH2—CH═CH—;
- (4) —CH═CH—CH═CH—;
- (5) —O—CH2—CH(ONO2)—CH2—;
- (6) —O—C(O)—CH═CH—;
- (7) —(CH2)2—C(O)—ND1-;
- (8) —(CH2)3—C(O)—;
- (9) —CH2—CH(OD1)—CH(OD1)—CH2—;
- (10) —S—(CH2)3—;
- R12 is:
- (1) —ND1-C(O)—(CH2)k—CH3;
- (2) —(CH2)k—C(O)—OD1;
- (3) —C(O)—(CH2)k—CH3;
- (4) halo;
- (5) —ND1-C(O)—N(C2H5)2;
- (6) —CH2—C(O)—N(H)D1;
- (7) —O—C(O)—CH3;
- (10) —CH2—O—(CH2)2—O—CH(CH3)2;
- (11) methyl;
- or
- (12) —(CH2)2—O—CH3;
- R13 is a hydrogen, methyl or halo;
- R14 is a hydrogen or a lower alkyl;
- R15 at each occurrence is independently selected from —OCH3, —OD1, —NO2, methyl or ND1-S(O)2—CH3;
- k is an integer from 0 to 4;
- D1 is a hydrogen, K or K′;
- K is —(W3)a-Eb-(C(Re)(Rf))p1-Ec-(C(Re)(Rf))x—(W3)d—(C(Re)(Rf))y—(W3)i-Ej-(W3)g—(C(Re)(Rf))z—V3;
- K′ is —(W3)a-Eb-(C(Re)(Rf))p1-Ec-(C(Re)(Rf))x—(W3)d—(C(Re)(Rf))y—(W3)i-Ej-(W3)g—(C(Re)(Rf))z—Re;
- V3 is:
- R24 is —C6H4R29, —CN, —S(O)2—C6H4R29, —C(O)—N(Ra)(Ri), —NO2, —C(O)—OR25 or —S(O)2—R25;
- R25 is an aryl group, a lower alkyl group, a haloalkyl group, a hydroxyalkyl group or an arylalkyl group;
- R26 is —C(O)— or —S(O)2—;
- R29 is a hydrogen, —CN, —S(O)2—R25, —C(O)—N(Ra)(Ri), —NO2 or —C(O)—OR25;
- T′ is oxygen, sulfur or NR6;
- R6 is a hydrogen, a lower alkyl group, an aryl group;
- a, b, c, d, g, i and j are each independently an integer from 0 to 3;
- pi, x, y and z are each independently an integer from 0 to 10;
- W at each occurrence is independently —C(O)—, —C(S)—, -T3-, —(C(Re)(Rf))h—, —N(Ra)Ri, an alkyl group, an aryl group, a heterocyclic ring, an arylheterocyclic ring, —(CH2CH2O)q1— or a heterocyclic nitric oxide donor;
- E at each occurrence is independently -T3-, an alkyl group, an aryl group, —(C(Re)(Rf))h—, a heterocyclic ring, an arylheterocyclic ring, —(CH2CH2O)q1— or Y3;
- Y3 is:
- T is a —S(O)o—;
- a carbonyl or a covalent bond;
- o is an integer from 0 to 2;
- Rj and Rk are independently selected from an alkyl group, an aryl group, or Rj and Rk taken together with the nitrogen atom to which they are attached are a heterocylic ring;
- T3 at each occurrence is independently a covalent bond, a carbonyl, an oxygen, —S(O)o— or —N(Ra)Ri;
- h is an integer form 1 to 10;
- q1 is an integer from 1 to 5;
- Re and Rf are each independently a hydrogen, an alkyl, a cycloalkoxy, a halogen, a hydroxy, an hydroxyalkyl, an alkoxyalkyl, an arylheterocyclic ring, an alkylaryl, an alkylcycloalkyl, an alkylheterocyclic ring, a cycloalkylalkyl, a cycloalkylthio, an arylalklythio, an arylalklythioalkyl, an alkylthioalkyl, a cycloalkenyl, an heterocyclicalkyl, an alkoxy, a haloalkoxy, an amino, an alkylamino, a dialkylamino, an arylamino, a diarylamino, an alkylarylamino, an alkoxyhaloalkyl, a sulfonic acid, a sulfonic ester, an alkylsulfonic acid, an arylsulfonic acid, an arylalkoxy, an alkylthio, an arylthio, a cyano, an aminoalkyl, an aminoaryl, an aryl, an arylalkyl, an alkylaryl, a carboxamido, an alkylcarboxamido, an arylcarboxamido, an amidyl, a carboxyl, a carbamoyl, an alkylcarboxylic acid, an arylcarboxylic acid, an alkylcarbonyl, an arylcarbonyl, an ester, a carboxylic ester, an alkylcarboxylic ester, an arylcarboxylic ester, a sulfonamido, an alkylsulfonamido, an arylsulfonamido, an alkylsulfonyl, an alkylsulfonyloxy, an arylsulfonyl, arylsulphonyloxy, a sulfonic ester, an alkyl ester, an aryl ester, a urea, a phosphoryl, a nitro, —U3—V5, V6, —(C(Ro)(Rp))k1—U3—V5, —(C(Ro)(Rp))k1—U3—V4, —(C(Ro)(Rp))k1—U3—C(O)—V6, or Re and Rf taken together with the carbons to which they are attached form a carbonyl, a methanthial, a heterocyclic ring, a cycloalkyl group, an aryl group, an oxime, an imine, a hydrazone, a bridged cycloalkyl group,
- Ro and Rp are each independently a hydrogen, an alkyl, a cycloalkoxy, a halogen, a hydroxy, an hydroxyalkyl, an alkoxyalkyl, an arylheterocyclic ring, an alkylaryl, an alkylcycloalkyl, an alkylheterocyclic ring, a cycloalkylalkyl, a cycloalkylthio, an arylalklythio, an arylalklythioalkyl, an alkylthioalkyl a cycloalkenyl, an heterocyclicalkyl, an alkoxy, a haloalkoxy, an amino, an alkylamino, a dialkylamino, an arylamino, a diarylamino, an alkylarylamino, an alkoxyhaloalkyl, a sulfonic acid, a sulfonic ester, an alkylsulfonic acid, an arylsulfonic acid, an arylalkoxy, an alkylthio, an arylthio, a cyano an aminoalkyl, an aminoaryl, an aryl, an arylalkyl, an alkylaryl, a carboxamido, an alkylcarboxamido, an arylcarboxamido, an amidyl, a carboxyl, a carbamoyl, an alkylcarboxylic acid, an arylcarboxylic acid, an alkylcarbonyl, an arylcarbonyl, an ester, a carboxylic ester, an alkylcarboxylic ester, an arylcarboxylic ester, a sulfonamido, an alkylsulfonamido, an arylsulfonamido, an alkylsulfonyl, an alkylsulfonyloxy, an arylsulfonyl, arylsulphonyloxy, a sulfonic ester, an alkyl ester, an aryl ester, a urea, a phosphoryl, a nitro, —U3—V5, V6, or Ro and Rp taken together with the carbons to which they are attached form a carbonyl, a methanthial, a heterocyclic ring, a cycloalkyl group, an aryl group, an oxime, an imine, a hydrazone a bridged cycloalkyl group,
- V4 is V3 or V6;
- U3 is an oxygen, sulfur or —N(Ra)Ri;
- V5 is —NO or —NO2 (i.e. an oxidized nitrogen);
- V6 is:
- Z5 is —CH2 or oxygen;
- Z6 is —CH or nitrogen;
- k1 is an integer from 1 to 3;
- k1 is an integer from 1 to 3;
- Ra is a lone pair of electrons, a hydrogen or an alkyl group;
- Ri is a hydrogen, an alkyl, an aryl, an alkylcarboxylic acid, an arylcarboxylic acid, in alkylcarboxylic ester, an arylcarboxylic ester, an alkylcarboxamido, an arylcarboxamido, an alkylaryl, an alkylsulfinyl, an alkylsulfonyl, an alkylsulfonyloxy, an arylsulfinyl, an arylsulfonyl, an arylsulphonyloxy, a sulfonamido, a carboxamido, a carboxylic ester, an aminoalkyl, an aminoaryl, —CH2—C—(U3—V5)(Re)(Rf), a bond to an adjacent atom creating a double bond to that atom or —(N2O2—).M1+, wherein M1+ is an organic or inorganic cation;
- and
- with the proviso that the compounds of Formula (I) must contain at least one heterocyclic nitric oxide donor group linked to the β-adrenergic antagonist through an oxygen atom, a nitrogen atom or a sulfur atom;
- wherein the compound of Formula (II) is:
- wherein:
- Y4 is:
- X4 is:
- (1) methyl;
- Z4 and Z4′ are independently selected from a methyl or a hydrogen;
- R16 is:
- (1) hydrogen;
- (2) —C(O)—N(D1)H;
- (3) —S(O)—CH3;
- or
- (4) —S(O)2—N(D1)H;
- R17 is a hydrogen, —OCH3 or —NO2;
- o1 is an integer from 0 to 2;
- R15, U3 and D1 are as defined herein;
- and
- with the proviso that the compounds of Formula (II) must contain at least one heterocyclic nitric oxide donor group linked to the β-adrenergic antagonist through an oxygen atom, a nitrogen atom or a sulfur atom;
- wherein the compound of Formula (III) is:
- wherein:
- X6 is:
- (1) —U3D1;
- (2) —O—CH2—CH3;
- or
- Y6 is:
- (1) —CH2—S—R21;
- W6 is:
- Z7 is:
- (1) hydrogen;
- (2) methyl;
- or
- (3) —(CH2)4—N(H)D1;
- R19 and R20 are a hydrogen;
- or
- R19 and R20 taken together are an oxo;
- or
- R20 and W6 taken together are:
- R21 is:
- (1) —C(O)—CH2—CH3;
- (2) hydrogen;
- (3) K;
- (4) K′;
- or
- R22 is —U3D1 or —OCH2—CH3;
- D1, U3, K and K′ are as defined herein;
- and
- with the proviso that the compounds of Formula (III) must contain at least one heterocyclic nitric oxide donor group linked to the angiotensin-converting enzyme (ACE) inhibitor through an oxygen atom, a nitrogen atom or a sulfur atom;
- wherein the compound of Formula (IV) is:
- wherein:
- B6 is:
- (2) a nitrogen;
- G6 is:
- D6 is:
- or B6 and D6 taken together form a phenyl ring;
- Q6 is a hydrogen;
- or
- B6 is a nitrogen and O6 is CH9 and taken together form the ring:
- U3 and D1 are as defined herein;
- and
- with the proviso that the compounds of Formula (IV) must contain at least one heterocyclic nitric oxide donor group linked to the angiotensin-converting enzyme (ACE) inhibitor through an oxygen atom, a nitrogen atom or a sulfur atom;
- wherein the compound of Formula (V) is:
- wherein:
- X7 is a hydrogen;
- Y7 is
- or X7 and Y7 taken together are:
- R23 is a hydrogen or —OCH3;
- R22, U3 and D1 are as defined herein;
- and
- with the proviso that the compounds of Formula (V) must contain at least one heterocyclic nitric oxide donor group linked to the angiotensin-converting enzyme (ACE) inhibitor through an oxygen atom, a nitrogen atom or a sulfur atom.